CA2100084A1 - Methode de prevention des lesions inflammatoires - Google Patents

Methode de prevention des lesions inflammatoires

Info

Publication number
CA2100084A1
CA2100084A1 CA002100084A CA2100084A CA2100084A1 CA 2100084 A1 CA2100084 A1 CA 2100084A1 CA 002100084 A CA002100084 A CA 002100084A CA 2100084 A CA2100084 A CA 2100084A CA 2100084 A1 CA2100084 A1 CA 2100084A1
Authority
CA
Canada
Prior art keywords
agent
antibody
mol
binding
neutrophil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002100084A
Other languages
English (en)
Inventor
James R. Rusche
Daniel P. Witt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repligen Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2100084A1 publication Critical patent/CA2100084A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002100084A 1991-01-11 1992-01-10 Methode de prevention des lesions inflammatoires Abandoned CA2100084A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64007191A 1991-01-11 1991-01-11
US640,071 1991-01-11

Publications (1)

Publication Number Publication Date
CA2100084A1 true CA2100084A1 (fr) 1992-07-12

Family

ID=24566733

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002100084A Abandoned CA2100084A1 (fr) 1991-01-11 1992-01-10 Methode de prevention des lesions inflammatoires

Country Status (4)

Country Link
EP (1) EP0565642A1 (fr)
JP (1) JPH06505969A (fr)
CA (1) CA2100084A1 (fr)
WO (1) WO1992011870A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US5646251A (en) * 1993-11-05 1997-07-08 The Board Of Trustees Of Leeland Stanford Jr. Univ. Alloreaction-associated antigen (ARAG): a novel member of the immunoglobulin gene superfamily
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
WO1998037914A1 (fr) * 1997-02-26 1998-09-03 Toray Industries, Inc. Remedes contre l'hepatite
WO2001070266A2 (fr) 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Methode d'inhibition de la stenose et de la restenose
WO2025202213A1 (fr) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Nanoparticule lipidique chargée d'agent antitumoral et fonctionnalisée pour cibler des cellules immosuppressives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935234A (en) * 1987-06-11 1990-06-19 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
NZ229922A (en) * 1988-07-18 1992-04-28 Chiron Corp Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions

Also Published As

Publication number Publication date
JPH06505969A (ja) 1994-07-07
WO1992011870A1 (fr) 1992-07-23
EP0565642A1 (fr) 1993-10-20

Similar Documents

Publication Publication Date Title
Harlan Leukocyte adhesion deficiency syndrome: insights into the molecular basis of leukocyte emigration
EP0528931B1 (fr) Anticorps anti-molecule 1 d'adherence intercellulaire chimerique adaptes au modele humain, procede de preparation et d'utilisation
US5091178A (en) Tumor therapy with biologically active anti-tumor antibodies
EP0625912B1 (fr) Traitement de l'inflammation intestinale
US20050281811A1 (en) Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
Nasi et al. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside
KR100475492B1 (ko) 항종양제로서의 림프독소-α/β 복합체 및항-림프독소-β수용체 항체
BG66149B1 (bg) Използване на антитяло хомолог като антагонист на интегрин алфа-4 субединица за получаване на фармацевтичен състав за лечение на фиброзни състояния
AU2008202838A1 (en) Combination therapy
SK77393A3 (en) Pharmaceutical mixture for treatment of illnesses by inhibition of intercellular adhesion by elam-1
CA2134966C (fr) Anticorps specifiques contre de multiples molecules d'adhesion
Iwahashi et al. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model
NZ259901A (en) Anti-lfa monoclonal antibody preparations and their use in preventing organ rejection
CA2100084A1 (fr) Methode de prevention des lesions inflammatoires
Kyan-Aung et al. Vascular cell adhesion molecule-1 and eosinophil adhesion to cultured human umbilical vein endothelial cells in vitro
EP0606391B1 (fr) Inhibition du retrecissement vasculaire par l'utilisation d'anticorps anti-padgem
US20030139579A1 (en) LO-CD2b antibody and uses thereof for inhibiting T cell activation and proliferation
WO1995013093A1 (fr) Traitement d'un patient avant une transplantation
WO1997035614A1 (fr) Utilisation d'anticorps contre la glycoproteine cd48 pour le traitement des lymphomes et des leucemies des cellules t et b
EP0686044B1 (fr) Inhibition de l'hyperplasie de l'intima par anticorps des recepteurs du facteur de croissance derive des plaquettes
US20020081305A1 (en) Altering the properties of cells or of particles with menbranes derived from cells by means of lipid-modified proteinaceous molecules
Pathy Patent Evaluation on Monoclonal Antibody (MAB) Therapy with Binding Specificity to CD20 B-Cell Surface Antigen Bp35 and the Manufacturing Process of Biological & Antibodies and Derivatives
Majima et al. Defective mononuclear cell antibody-dependent cellular cytotoxicity (ADCC) in patients with leukocyte adhesion deficiency emphasizing on different CD11/CD18 requirement of FcγRI versus FcγRII in ADCC
EP0791360A2 (fr) Traitement du choc septique avec des anticorps anti-TNF
Stevenson The prospects for treating cancer with antibody

Legal Events

Date Code Title Description
FZDE Dead